Inferior outcome after hip resurfacing arthroplasty than after conventional arthroplasty: Evidence from the Nordic Arthroplasty Register Association (NARA) database, 1995 to 2007 by Johanson, Per-Erik et al.
Acta Orthopaedica 2010; 81 (5): 535–541  535
Inferior outcome after hip resurfacing arthroplasty than after 
conventional arthroplasty
Evidence from the Nordic Arthroplasty Register Association (NARA) database, 
1995 to 2007
Per-Erik Johanson1, Anne Marie Fenstad2, Ove Furnes2,3, Göran Garellick1, Leif I Havelin2,3,   
Sören Overgaard4,5, Alma B Pedersen5, and Johan Kärrholm1
1The Swedish Hip Arthroplasty Register, Department of Orthopedics, Institute of Surgical Sciences, Sahlgrenska University Hospital, University of 
Gothenburg, Sweden, 2The Norwegian Arthroplasty Register, Department of Orthopedic Surgery, Haukeland University Hospital, Bergen; 3Department of 
Surgical Sciences, University of Bergen, Norway, 4The Danish Hip Arthroplasty Register and Department of Orthopedic Surgery, Clinical Institute, Odense 
University Hospital, Odense; 5The Danish Hip Arthroplasty Register and Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark 
Correspondence: per-erik.johanson@vgregion.se  
Submitted 09-11-02. Accepted 10-05-24
Open Access - This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, 
distribution, and reproduction in any medium, provided the source is credited.
DOI 10.3109/17453674.2010.525193
Background and purpose   The reported outcomes of hip resurfac-
ing arthroplasty (HRA) vary. The frequency of this procedure in 
Denmark, Norway, and Sweden is low. We therefore determined 
the outcome of HRA in the NARA database, which is common to 
all 3 countries, and compared it to the outcome of conventional 
total hip arthroplasty (THA). 
Methods   The risk of non-septic revision within 2 years was 
analyzed in 1,638 HRAs and compared to that for 172,554 con-
ventional total hip arthroplasties (THAs), using Cox regression 
models. We calculated relative risk (RR) of revision and 95% con-
fidence interval.
Results   HRA had an almost 3-fold increased revision risk com-
pared to THA (RR = 2.7, 95% CI: 1.9–3.7). The difference was 
even greater when HRA was compared to the THA subgroup of 
cemented THAs (RR = 3.8, CI: 2.7–5.3). For men below 50 years 
of age, this difference was less pronounced (HRA vs. THA: RR = 
1.9, CI: 1.0–3.9; HRA vs. cemented THA: RR = 2.4, CI: 1.1–5.3), 
but it was even more pronounced in women of the same age group 
(HRA vs. THA: RR = 4.7, CI: 2.6–8.5; HRA vs. cemented THA: 
RR = 7.4, CI: 3.7–15). Within the HRA group, risk of non-septic 
revision was reduced in hospitals performing ≥ 70 HRAs annually 
(RR = 0.3, CI: 0.1–0.7) and with use of Birmingham hip resurfac-
ing (BHR) rather than the other designs as a group (RR = 0.3, CI: 
0.1–0.7). Risk of early revision was also reduced in males (RR = 
0.5, CI: 0.2–0.9). The femoral head diameter alone had no statisti-
cally significant influence on the early revision rate, but it elimi-
nated the significance of male sex in a combined analysis.
Interpretation   In general, our results do not support continued 
use of hip resurfacing arthroplasty. Men had a lower early revi-
sion rate, which was still higher than observed for all-cemented 
hips. Further follow-up is necessary to determine whether HRA 
might be useful as an alternative in males.
 
           
 
The  development  of  contemporary  metal-on-metal  (MOM) 
bearings has stimulated renewed interest in hip resurfacing 
arthroplasty (HRA) of the hip. These devices are available 
in different designs, most of which are hybrid concepts with 
cemented  femoral  and  uncemented  acetabular  components. 
The proposed advantages of HRA compared to conventional 
total  hip  arthroplasty  (THA)  include  improved  range  of 
motion and hip function, bone preservation, lower dislocation 
rates, and easier and safer revision procedures in case of fail-
ure (Shimmin et al. 2008). Because of the low wear character-
istics observed in the laboratory and in clinical situations, the 
MOM bearing is thought to be especially suitable for patients 
with a long life expectancy (McMinn and Daniel 2006).
Early  reports  from  specialized  centers  have  shown  high 
survival  rates:  97.8–99.8%  after  3–5  years  (Daniel  et  al. 
2004, Treacy et al. 2005, Hing et al. 2007). Other authors 
have reported inferior results (Kim et al. 2008, Stulberg et 
al. 2008). Narrowing of patient selection criteria and refine-
ment of surgical technique have improved the results in some 
case series (Mont et al. 2007, Amstutz et al. 2007). Several 
studies have shown that HRA is associated with a long learn-
ing curve. Early failures or inadequate implant positioning 
occurred at the beginning of the learner’s case series, which 
tended to decrease thereafter (Marker et al. 2007, Witjes et al. 
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caused by femoral neck fracture and aseptic loosening of the 
femoral component. Thus, there are several indications that 
the outcome of HRA is influenced by patient selection, surgi-
cal technique, and experience in using this type of implant. 
Short- and medium-term results of HRA have previously 
been  reported  from  national  joint  replacement  registries. 
There has been a rapid increase in the use of HRA, with vary-
ing percentages of HRA relative to the total volume of THAs 
reported by different registries (Kärrholm et al. 2008, CJRR 
2008-2009,  AOANJRR  2008).  Reports  of  inferior  results, 
except in younger males with primary osteoarthritis, are most 
probably responsible for the recent tendency of decreasing 
use of HRA—especially in females (AOANJRR 2008). Fur-
ther reports of comparatively rare but serious complications 
(Pandit et al. 2008, Hart et al. 2009, Ollivere et al. 2009) have 
probably also contributed to this tendency. Poor results after 
revision of failed HRA, equal to those obtained after revi-
sion of THA (AOANJRR 2008), may also have contributed to 
more restricted use. 
We analyzed the early outcome concerning aseptic revisions 
within 2 years of HRA and compared it to that of THA in the 
common database of the Nordic Arthroplasty Register Asso-
ciation (Havelin et al. 2009). We also evaluated the extent to 
which outcome was influenced by implant design, number of 
procedures per hospital, and femoral head size. 
Patients and methods
Inclusion criteria 
The NARA database consists of data on individual total hip 
replacements compiled from the 3 national joint replacement 
registry databases of Denmark, Norway, and Sweden (Havelin 
et al. 2009). At the time of this analysis, the database covered 
309,290 operations performed between 1995 and 2007. 
To reduce the skew in demographic distribution between 
patients operated with HRA and those operated with THA, 
cases  older  than  73  years  of  age  (the  oldest  patient  oper-
ated with HRA) and those with femoral neck fracture were 
excluded (there was 1 case in the HRA group, probably a reg-
istration error and 34,944 in the THA group). 461 hips (0.3%) 
with missing information about type of implant, 4 about oper-
ated side, and one about gender were also excluded, leaving 
1,638 HRAs and 172,554 THAs available for analysis (Table 
1). Due to the short follow-up in the HRA group (mean 1.8 
years (SD 1.5); THA: 5.1 (SD 3.5)) revision within 2 years 
was used as endpoint. Only aseptic revisions were included. 
Revision was defined as removal or exchange of at least one 
of the components. 
Statistics
Kaplan-Meier  survival  analysis  was  used  to  estimate  the 
unadjusted cumulative revision rates, presented as cumulative 
survival  (CS)  with  95%  confidence  interval  (CI). Adjusted 
revision rates were calculated using Cox multiple regression 
analysis. The proportional hazards assumption was controlled 
for by performing hazard function and log-minus-log plots for 
strata of each covariate separately. Plots were investigated for 
acceptable proportionality between hazard functions of the 
different covariate strata and for strictly parallel log-minus-
log plots. No crossing or clearly deviating lines were accepted. 
No continuous variables were entered in the model. 
Inclusion of bilateral cases in a survival analysis violates 
the basic assumption that all cases analyzed are independent. 
However, several reports have shown that the effect of includ-
ing bilateral cases in studies of hip and knee joint prosthe-
sis survival is negligible (Schwarzer et al 2001, Robertsson 
and Ranstam 2003, Lie et al 2004). We therefore included all 
available cases to maximize statistical power. Relative risk 
(RR) estimates were calculated and presented with 95% CI. 
The level of significance was 95%. We used the SPSS statisti-
cal software package version 16.0.
Hip resurfacing vs. conventional implant designs
HRA was compared to all-cemented THA and THA as a group 
(all-cemented,  non-cemented,  hybrid,  and  inverse  hybrids) 
with adjustment for age at surgery, sex, operated side, diag-
nosis, and nationality, using Cox multiple regression. Age was 
classified as 0–49 years, 50–59 years, or ≥ 60 years. Diag-
nosis was entered as primary or secondary osteoarthritis, the 
latter  including  non-fracture  diagnoses  other  than  primary 
osteoarthritis. In addition, stratified analyses were done for 
males and females aged 49 years and younger, and between 
50–73 years of age, dividing the HRA group by its mean age.
Table 1.The total study group of 174,192 THA patients up to 73 years 
of age (those with femoral fractures excluded) who were operated 
1995 through 2007
  HRA  THA  p-value
  n = 1,638  n = 172,554 
Percentage males  68  43  < 0.001 a
Mean age, years (range)  51 (15–73)  62 (12–73)  < 0.001 b
Age groups, %
  < 30    2.1    0.6
  30–39    8.9    1.8 
  40–49  31    6.1
  50–59  42  23
  60–74  17  69  < 0.001 a
Operated side, % (no.)
  Right   53 (861)  54 (93,866)  0.1 a
Diagnosis, %
  Primary osteoarthritis  89  85
  Inflammatory arthritis    2.2    4.3
  Childhood diseases    6.5    6.1
  Idiopathic femoral 
     head necrosis    0.9    2.7
  Other    1.0    2.1  < 0.001 a
a Chi-squared test.
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Hip resurfacing group
The  HRA  group  was  further  analyzed  with  regard  to  the 
influence of age at surgery (classified as 0–49 years or ≥ 50 
years), sex, diagnosis, implant design, and number of HRAs 
performed per hospital (2 groups: total numbers < 70 or ≥ 70) 
on risk of revision within 2 years. The limit of 70 patients 
was set arbitrarily based on the actual distribution of cases per 
hospital, and also so that each country contributed with at least 
one high-volume hospital. Operated side was not included in 
the analysis since this covariate did not fulfill the proportional 
hazards assumption in this group, showing an increase in revi-
sion rate for left-sided hips at the end of the 2-year period. The 
4 most commonly used implant designs were studied (ASR, 
DePuy; BHR, Smith and Nephew; Durom, Zimmer; ReCap, 
Biomet) (Table 2), resulting in a study group of 1,611 hips 
with 35 revisions. The remaining 27 hips of other designs were 
excluded from this analysis because of a clearly deviating 
survival function, thus not fulfilling the proportional hazards 
assumption necessary for the Cox regression model. We did 
not adjust for nation in the analysis of HRA designs because 
all designs of HRA were not used in all 3 countries. Informa-
tion about femoral head diameter was available in 1,552 cases. 
To reduce the influence of missing observations and to investi-
gate correlation with sex, femoral head diameter (classified as 
≤ 44 mm, 45–49 mm, 50–54 mm, and ≥ 55 mm) was added in 
separate evaluations. This is the same diameter classification 
as in the Australian Registry report (AOANJRR 2008).
Ethics
The  study  was  approved  by  the  Danish  Data  Protection 
Agency (J. no. 2008-41-2024), the Norwegian Social Science 
Data Services, and the Swedish Data Inspection Board.
 
Results
Demographics and revisions
68% of patients were male in the HRA group and 43% were 
male in the THA group. Mean age of HRA cases was 51 (15–
73) years and mean age of THA cases was 62 (12–73) years. 
Primary osteoarthritis was slightly more common in the HRA 
group (89%) than in the THA group (85%) (Table 1). 107 
of the 174 cases with secondary arthritis in the HRA group 
were classified as secondary to childhood diseases. The HRA 
designs in the database are listed in Table 2. The 1-year unad-
justed Kaplan-Meier-estimated cumulative revision rate was 
1.8% for HRA and 0.7% for THA, and the 2-year rates were 
3.3% and 1.2% (Table 3). The main reason for early revision 
of hip resurfacings was fracture, whereas THAs were revised 
early mainly because of dislocation. Unspecified reasons for 
revision (“other”) were recorded in 27% of the HRA revisions 
as compared to 9% in THA revisions, the high numbers in the 
former group being due to the limitations of detailed revision 
data that were accessible. 
Hip resurfacing vs. conventional implant designs—
overall results 
Figure 1 shows unadjusted Kaplan-Meier-estimated cumula-
tive survival for the HRAs and for the total group of THA 
implants. In the Cox regression analysis, HRA showed an 
increased  risk  of  early  aseptic  revision  compared  to  THA 
(RR = 2.7, CI: 1.9–3.7; p < 0.001) and all-cemented THA 
(RR = 3.8, CI: 2.7–5.3; p < 0.001).
Hip resurfacing vs. conventional implant designs—
age and sex analysis 
In the older age group of men, 50–73 years, the early revision 
rate of HRA was increased compared to all cemented THAs 
(RR = 2.1, CI: 1.1–3.9), but not when compared to the com-
pound group of all variations of THAs. Conversely, females 
Table 2. HRA implant designs in the 
NARA database, 1995–2007
Implant design  %   n
 
BHR  48   780
Durom  21   344
ASR  18   296
ReCap  12   191
Adept      0.9   14
Cormet (+/- HA)  0.4   7
McMinn  0.4   6
Total     1,638
Table 3. Unadjusted revision rates and reasons for aseptic revision up to 2 years
  HRA  THA  p-value
  n=1,638  n=172,554
 
Crude aseptic revision rate, % (no.)
  1 year  1.6 (26)  0.7 (1251)
  2 years  2.4 (40)  1.1 (1954)
Kaplan-Meier unadjusted non-septic 
  cumulative revision rate, % (95% CI)
  1 year  1.8 (1.1–2.4)  0.8 (0.7–0.8)
  2 years  3.3 (2.2–4.3)  1.2 (1.2–1.3)  < 0.001 a
Reason for revision up to 2 years, % (no.)
  Aseptic loosening  25 (10)  25 (497)
  Fracture  40 (16)    9 (176)
  Dislocation    0  50 (967)
  Pain only    5 (2)    4 (88)
  Other  30 (12)  12 (226)  < 0.001 b
      
a Log-rank test.
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between 50 and 73 years of age with HRA had an increased 
risk of early revision both compared to THA (RR = 3.2, CI: 
1.6–6.5) and to all-cemented THA (RR = 4.0, CI: 2.0–8.1). In 
the younger subset of males (≤ 49 years), the early revision 
rate of HRA was again increased compared to all-cemented 
THA (RR = 2.4, CI: 1.1–5.3), but not when compared to THA 
as a whole. In younger females, the risk of early revision of 
HRA implants was 4.7 (CI: 2.6–8.5) compared to THA as a 
whole and 7.4 (CI: 3.7–15) compared to all-cemented THA 
(Table 4).
Hip resurfacing group: the 4 most commonly used 
designs
The mean overall follow-up for ASR was 1.1 (0.0–3.1) years; 
for BHR it was 2.1 (0.0–8.1) years, for Durom it was 2.1 
(0.0–5.8) years, and for ReCap it was 1.1 (0.0–2.8) years. 
Males had a 50% reduced risk of early revision (RR = 0.5, CI: 
0.2–0.9) (Table 5). Repeat of the analysis including also the 
femoral head diameter reduced the number of observations to 
1,552. In this combined analysis, neither femoral head diam-
eter nor gender had any statistically significant influence on 
early revision rate (Table 6). Finally, in performing the same 
analysis but omitting gender, femoral head diameter alone did 
not have any statistically significant influence on early revi-
sion rate (data not shown). Femoral heads with diameters of 
Figure 1. Unadjusted Kaplan-Meier-estimated cumulative survival (CS ± 1.96 
SE) for 1,638 HRAs with estimated 2-year CS of 96.7% (95% CI: 95.7–97.8; no. 
remaining = 547) and 172,554 THAs with estimated 2-year CS of 98.8% (95% 
CI: 98.7–98.8; no. remaining = 135,173); p < 0.001 (log-rank test).
Table 4. Age- and sex-stratified relative risk of aseptic revision within 2 years after primary operation. HRA was compared to 
all other types of conventional THA or only to the all-cemented (all-c THA) subpopulation. Data are based on a Cox regression 
model adjusted for operated side, nationality, diagnosis, and type of implant
    Adjusted revision risk (95% CI)  Number of cases (No. of revisions)
  HRA/THA     p-value  HRA/all-c THA     p-value  HRA  THA  all-c THA
Age < 50 years
  Males  1.9 (1.0–3.9)  0.07  2.4 (1.1–5.3)  0.04  460 (9)    7,183 (109)    1,782 (18)
  Females  4.7 (2.6–8.5)  < 0.001  7.4 (3.7–15)  < 0.001  221 (13)    7,486 (114)    2,242 (21)
Age 50–73 years         
  Males  1.7 (0.9–3.1)  0.1  2.1 (1.1–3.9)  0.02  653 (10)  67,134 (807)  43,725 (387)
  Females  3.2 (1.6–6.5)  0.001  4.0 (2.0–8.1)  < 0.001  304 (8)  90,751 (924)  64,308 (482)
Table 5. Relative risk of aseptic revision up to 2 years (RR) with 95% 
confidence interval (CI) in 1,611 hip resurfacings (35 revisions). Data 
are based on a Cox regression model including age (< 50 or ≥ 50 
years), sex, diagnosis, hospital production volume, and the 4 most 
common HRA designs with BHR as reference 
  RR  95% CI  p-value
Hospital production volume: 
  < 70 / ≥ 70 procedures  3.7  1.5–8.9  0.003
Hip resurfacing design:     
  BHR (reference)  1  –  0.02
  Durom  3.1  1.2–7.8  0.02
  ASR  2.7  1.0–7.4  0.06
  ReCap  5.4  1.8–16  0.003
Male / female  0.5  0.2–0.9  0.03
Age (< 50 / 50–73 years)  1.5  0.8–3.1  0.2
Primary / secondary OA  1.0  0.4–2.8  0.9
Table 6. The same type of analysis as in Table 5 except that femoral 
head diameter (categorized as ≤ 44mm, 45–49 mm, 50–54 mm, and 
≥ 55 mm) has been added, resulting in 1,552 hip resurfacings (35 
revisions) available for analysis 
  RR  95% CI  p-value
     
Hospital production volume: 
  < 70 / ≥ 70 procedures   3.7  1.5–8.8  0.004
Hip resurfacing design:     
  BHR (reference)  1  –  0.02
   Durom  3.1  1.2–7.8  0.02
   ASR  2.3  0.8–6.5  0.1
   ReCap  5.4  1.8–17  0.003
Male / female  0.7  0.3–1.8  0.5
Femoral head diameter     
   < 44 mm (reference)  1  –  0.3
   45–49 mm  0.8  0.3–2.4  0.8
   50–54 mm  0.4  0.1–1.4  0.2
   > 55 mm   0.9  0.2–4.2  0.9
Age (< 50 / 50–73 years)  1.4  0.7–3.0  0.3
Primary / secondary OA  1.2  0.4–3.4  0.7Acta Orthopaedica 2010; 81 (5): 535–541  539
50–54 mm had lower revision rates, but the difference was not 
significant. Hospitals that had performed less than 70 HRA 
procedures had an almost 4 times increased risk of early revi-
sion (RR = 3.7; CI: 1.5–8.8) compared to those with a longer 
record (Tables 5 and 6). 
When we compared the different HRA designs using BHR 
as a reference, Durom, ASR, and ReCap all had a higher risk of 
early revision, even though the difference with ASR was just 
outside the limit of statistical significance. CI for the Durom, 
ASR, and ReCap designs showed considerable span and over-
lap, and the analysis does not permit any ranking between 
them. Compared to the other designs pooled into one group, 
BHR had a lower adjusted risk of early revision (RR = 0.3, CI: 
0.1–0.7; p = 0.008). Figure 2 shows unadjusted Kaplan-Meier 
cumulative survival for those factors that turned out to have a 
statistically significant influence.
Discussion
National joint replacement registers reflect the broad use of 
joint prostheses. Good results reported from highly special-
ized centers are often not reproduced when a new implant 
design is introduced to all orthopedic surgeons, especially if 
the procedure is technically demanding and suitable only for a 
small patient population. Register reports correspond to obser-
vational studies and they may suffer from different types of 
bias. On the other hand, they survey large numbers of patients. 
In the 3 Scandinavian countries included in this study the 
frequency of these procedures is low, which underscores the 
value of compilation of the national databases.
 
that could be related to surgical and technical errors was high. 
With longer follow-up, other reasons for revision—and espe-
cially those related to loosening, wear, and biological reaction 
caused by wear-related debris or release of metal—can be sup-
posed to change the relative distribution of revisions in either 
direction. Also, there were relatively few revisions, permitting 
only a minimum of stratified analysis and increasing the sen-
sitivity to random effects of single revision cases.
In the total group of THA patients aged less than 74 years 
and with a non-fracture diagnosis, 461 hips were excluded 
because of missing information about type of implant. If a 
substantial fraction of those were HRA cases, we may have 
underestimated the risk of early revision after HRA. The crude 
revision rate in this group was 1.7% (8/461) with a mean age 
of 54 years, and the proportion of males was 52%, indicating 
a case mix closer to that of the HRA group than to that of the 
THA group or the combined group.
Hip resurfacing vs. conventional implant designs
Annual reports from national joint replacement registers have 
shown increased revision rates of hip resurfacing compared 
to conventional arthroplasty (NJR England and Wales 2009, 
Kärrholm et al. 2008, AOANJRR 2008). We could confirm 
this observation but found that for men of any age, there was 
no  statistically  significant  difference  in  early  revision  rate 
for THA as a group compared to HRA, but that there was a 
reduced revision rate for all-cemented THA vs HRA. In the 
British registry, the results of hip resurfacing are improved 
for males less than 55 years of age but they do not, however, 
match those of THA (NJR England and Wales 2009). In the 
Australian registry, the 3-year revision rate for HRA is the 
same as for THA in the group of patients less than 55 years of 
Figure 2. Unadjusted Kaplan-Meier-estimated cumulative survival (CS) of the group of the 4 most common 
types of HRA, subgroups with significant influence on early non-septic revision rate (CS ± 1.96SE). A. Hospital 
with ≥ 70 HRAs: n = 820, 2-year CS = 98.8% (95% CI: 97.9–99.8; no. remaining at 2 years = 269). Hospital with 
< 70 HRA: n = 791, 2-year CS = 95.5% (95% CI: 93.7–97.2; no. remaining at 2 years = 272); p < 0.001 (log-rank 
test). B. BHR: n = 780, 2-year CS = 98.8% (95% CI: 97.9–99.7; no. remaining at 2 years = 341). Non-BHR: 
n = 831, 2-year CS = 95.6% (95% CI: 93.8–97.3; no. remaining at 2 years = 200); p < 0.001 (log-rank test).
Limitations of the study
Our results may have been influenced 
by confounding. In the HRA group, 
there was more primary osteoarthritis 
and less inflammatory and other types 
of  secondary  OA  than  in  the  refer-
ence group, possibly favoring pros-
thesis  survival  in  the  HRA  cohort. 
Despite  the  use  of  an  upper  age 
limit,  patients  in  the  control  group 
had a higher mean age. These prob-
lems were adjusted for as far as pos-
sible by the use of regression models. 
Unmeasured  confounding,  such  as 
bone quality, the anatomy of the hip 
joint, and the preferences of patient 
and  surgeon  would  certainly  also 
influence the results, but these con-
siderations could not be addressed in 
our study. 
The  follow-up  was  short.  This 
means that the proportion of revisions 
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age, and the revision rate of HRA increases with age (Buergi 
and Walter  2007).  Studies  comparing  HRA  with  different 
types of THA for corresponding age groups have shown simi-
lar results (Pollard et al. 2006, Vail et al. 2006). However, in 
the NARA database there is a considerable increase in early 
revision risk for younger females (< 50 years) with HRA—
more than 7 times when compared to cemented THA—sug-
gesting that HRA is unsuitable for this patient group. This 
observation is based on 221 HRA cases with 13 revisions, 
which is a limitation.
The hip resurfacing group
In previous registry reports, the cumulative total revision rates 
for HRA after 1 year varied between 1.6% and 1.9% (NJR 
England and Wales 2007, AOANJRR 2008) and after 3 years 
they varied between 2.6% and 4.5% (AOANJRR 2008, NJR 
England and Wales 2009). In the Australian report, the cumu-
lative total revision rate reached 3.7% after 5 years (AOAN-
JRR 2008). The 2-year result for HRA in the NARA data-
base, with a cumulative 2-year revision rate of 3.7% including 
septic revisions, is close to the high range of these figures. 
The Australian, British, and Swedish registries have reported 
approximately twice the revision rate for women than for men 
(AOANJRR 2008, Kärrholm et al. 2008, NJR England and 
Wales 2009). To date, the Australian registry has had the larg-
est number of registered hip resurfacings, and a recent analysis 
of 12,093 HRAs with up to 8 years of follow-up has revealed 
an increased risk of revision with increasing age, with smaller 
femoral head size, with a primary diagnosis of developmental 
dysplasia, and for certain designs of prosthesis. On adjusting 
for femoral head size, female sex no longer remained as inde-
pendent risk factor (Prosser et al. 2010). A similar relation-
ship between sex and femoral head diameter has been reported 
from a single institution, with 655 BHRs at an average of 3.5 
years follow-up (McBryde et al. 2010).
In our analysis of HRA, we found that the revision rate for 
females was approximately doubled. Further studies concern-
ing different reasons for revision were not done due to the 
relatively  small  number  of  revisions.  In  addition,  femoral 
head diameter alone had no certain influence on early revision 
rate but our results suggest that there may be an association 
between sex and femoral head diameter, which could perhaps 
be  clarified  further  with  more  cases  and  longer  follow-up. 
We could not find any reduced revision risk with increased 
femoral head diameter or any increased risk with age or with 
secondary osteoarthritis. Our analysis did, however, include 
fewer patients and involved a shorter follow-up than the Aus-
tralian study.
We arbitrarily used a limit of 70 HRAs to separate low-
volume hospitals from high-volume hospitals. This limit was 
set so that all 3 countries should contribute with at least one 
hospital. This parameter should preferably be split up further 
to volume per surgeon, but such information is not available 
in the NARA database. Nonetheless, high volume according 
to our definition turned out to have an impact on the results in 
terms of revision. Based on repeated reports of inferior results 
of HRA, it can be expected that the frequency of these proce-
dures will decrease. If they will still be used in young males, 
it seems reasonable that the operations would become more 
centralized in the Scandinavian countries. During the time of 
collection of data in the NARA database for this study, such 
operations had already been performed in 48 different hospi-
tals (Denmark: n = 14; Norway: n = 7; Sweden: n = 27). 
4 designs could be analyzed separately. The Birmingham 
Hip Replacement (BHR) device stood out from the others as 
having a statistically significant better survival, which is con-
sistent with results from the Australian, British, and Swedish 
registries. 2 of the designs analyzed, ASR and ReCap, had a 
considerably shorter follow-up than BHR. However, assuming 
a fairly constant revision rate, this should have amplified the 
difference measured between BHR and these designs. On the 
other hand, the results for these 2 designs (ASR and ReCap) 
may be more likely to have been influenced by early learning 
curve problems, as described by Marker et al. (2007), Witjes 
et al. (2009), and Nunley et al. (2010).
Early  cup  loosening  has  been  reported  with  the  Durom 
acetabular component (Long et al. 2009). In the USA, this 
cup has a somewhat different coating with smaller pores than 
used in Europe. In our study, only 1 of the 16 Durom revisions 
included exchange of the cup. In all others, only the femoral 
component was replaced, suggesting that early cup loosening 
is not a problem with this variation in design. 
The reason for the good early performance of the BHR as 
found by us and others is not known. Also, previous reports 
have described favorable early results with this implant (Back 
et al. 2005, Daniel et al. 2004, Treacy et al. 2005). To our 
knowledge, there has not been any clinical study comparing 
different HRA designs. There are certain differences between 
designs regarding metallurgy, articulation clearance, material 
thickness, implant geometry, and recommended cementation 
technique but there is limited knowledge of how these proper-
ties affect outcome. One cadaveric study has shown that the 
BHR  femoral  component  has  superior  cement  penetration 
compared to other designs, including those used in this study 
(Beaulé et al. 2009), but the importance of this difference is 
unknown. Apart from metallurgical and design-related factors, 
other reasons such as instruments used during insertion, edu-
cational programs, and procedure frequency per surgeon may 
have had a positive influence. Such factors are important, but 
their true influence on the early complication rate is poorly 
understood, not least for hip resurfacings.
Conclusion
Hip resurfacing arthroplasty has a higher risk of early revision 
than  conventional  and  cemented THA.  Implant  design  has 
an influence on early revision rates, as do hospital procedure 
volumes. Our 2-year results from the NARA database do not 
support continued use of hip resurfacing arthroplasty. Further Acta Orthopaedica 2010; 81 (5): 535–541  541
follow-up is necessary to determine whether HRA might still 
be an alternative in males. 
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